Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA
A Randomized, Multicenter, Double-blind, Vehicle-controlled, Phase 2a Study to Assess the Safety, Pharmacokinetics, and Efficacy of PP405 in Adults With Androgenetic Alopecia
In the register
The register attaches this trial to PP405 (Pelage Pharmaceuticals), currently at “Phase 2” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Completed
- Declared phase
- Phase 2
- Sponsor
- Pelage Pharmaceuticals, Inc.
- Participants (registry)
- 78
- Start
- June 2024
- Primary completion
- July 2025
- Study completion
- October 2025
- Last registry update
- September 2026
- Countries
- United States
Conditions studied: Androgenetic Alopecia
Interventions: PP405 0.05% Topical Gel, PP405 0.05%, Topical Vehicle Gel, Topical Placebo
Other trials of PP405
Phase 2/3 Efficacy and Safety of PP405 in Adult Males
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.